PepGen Reports Positive Results from Early-Stage Drug Trial

Got story updates? Submit your updates here. ›

PepGen, a Boston-based biotechnology company, has announced positive topline results from the lowest dose cohort (5 mg/kg) in the ongoing Phase 1 clinical trial of its investigational drug. The company reported that the drug was well-tolerated and demonstrated encouraging signs of efficacy in this early stage of development.

Why it matters

PepGen's drug candidate represents a potential new treatment option for patients with serious medical conditions. Positive results from the initial Phase 1 trial are an important milestone that could pave the way for further clinical development and, if successful, eventual regulatory approval and availability of the drug.

The details

The Phase 1 study is designed to evaluate the safety, tolerability, and preliminary efficacy of PepGen's drug in healthy adult volunteers. In the latest update, the company reported that the 5 mg/kg dose was well-tolerated with no serious adverse events observed. Additionally, the drug showed signs of achieving the intended pharmacological effect, a key indicator of potential clinical benefit.

• The Phase 1 clinical trial of PepGen's drug is currently ongoing.
• The topline results announced on March 30, 2026 are from the lowest dose cohort (5 mg/kg) in the study.

What’s next

PepGen plans to continue evaluating higher doses of the drug in the ongoing Phase 1 trial to further assess its safety and efficacy profile. Pending positive results, the company may then initiate a larger Phase 2 clinical study to evaluate the drug's effectiveness in patients.